12:00 AM
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

VX-222: Additional Phase II data

Vertex reported interim data from 46 treatment-naïve patients with chronic HCV genotype 1a or 1b infection who were receiving twice-daily 400 mg VX-222 plus Incivek telaprevir and ribavirin in the interferon-free arms of the open-label, U.S. and New Zealand Phase II ZENITH trial. Of the 11 patients who were eligible to stop all treatment at week 12, 9 (82%) achieved an SVR defined as undetectable HCV RNA levels (<10 IU/mL) 4 weeks after the end of treatment (SVR4). All 5 evaluable patients with HCV genotype 1b infection achieved an SVR 12 weeks after the end...

Read the full 464 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >